Equities

STAAR Surgical Co

STAAR Surgical Co

Actions
Health CareMedical Equipment and Services
  • Price (USD)29.02
  • Today's Change-1.40 / -4.60%
  • Shares traded534.14k
  • 1 Year change-13.35%
  • Beta0.5939
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

  • Revenue in USD (TTM)341.22m
  • Net income in USD21.78m
  • Incorporated1986
  • Employees1.06k
  • Location
    STAAR Surgical Co1911 Walker AveMONROVIA 91016United StatesUSA
  • Phone+1 (626) 303-7902
  • Fax+1 (302) 636-5454
  • Websitehttps://www.staar.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Owens & Minor, Inc.10.66bn-48.79m997.02m13.70k--1.144.500.0935-0.6346-0.6346139.2711.352.097.2615.86778,172.30-0.95611.32-1.492.0720.7216.48-0.45760.56140.45192.030.68310.7983.801.87-284.47--25.91--
CeriBell Inc-100.00bn-100.00bn1.03bn----------------0.5919------------------------3.53--0.4912--74.47--20.72------
Pulse Biosciences Inc0.00-46.13m1.09bn56.00--13.79-----0.8069-0.80690.001.290.00----0.00-58.03-93.21-62.84-104.99-------12,332.25----0.00---100.00--27.85---15.20--
Artivion Inc376.97m-8.32m1.16bn1.50k--3.9377.393.08-0.2076-0.20769.117.060.4811.675.44251,316.00-1.07-2.20-1.15-2.3664.6365.51-2.22-5.344.041.070.5177--12.826.14-60.09--5.13--
Establishment Labs Holdings Inc151.35m-83.20m1.18bn857.00--26.30--7.82-3.11-3.115.621.610.53070.85252.72166,685.00-29.17-33.22-34.29-41.1266.0464.73-54.97-43.192.91-20.680.8114--2.1321.96-4.38--69.16--
BioLife Solutions Inc121.17m-53.87m1.22bn409.00--3.80--10.09-1.21-1.642.696.970.29991.995.39296,254.30-13.33-13.76-14.60-15.0441.2736.76-44.46-42.991.81-5.980.0651---11.4348.6552.49--86.35--
Alphatec Holdings Inc572.74m-177.87m1.32bn839.00------2.30-1.27-1.274.080.15460.80891.117.73682,644.80-25.12-30.97-32.00-39.4769.4766.02-31.06-46.221.15-3.660.9596--37.4539.38-23.36--67.92--
STAAR Surgical Co341.22m21.78m1.43bn1.06k66.243.3451.704.190.43810.43816.908.690.67632.033.15323,128.804.326.774.927.9078.7376.896.389.165.38--0.00020.0013.3721.07-46.1833.8551.95--
Adapthealth Corp3.26bn-217.76m1.44bn10.70k--0.94858.730.4409-1.64-1.6424.2311.270.709621.158.45304,912.50-4.57-4.34-5.14-4.8919.0318.28-6.44-6.470.99512.290.5757--7.73---1,169.99------
Inmode Ltd423.75m153.67m1.47bn581.0010.432.169.523.471.851.855.048.920.52391.5810.15729,339.1019.0031.3220.7735.6481.6484.4636.2639.659.91--0.000.008.3237.4922.5454.6513.10--
Myriad Genetics, Inc.823.60m-116.00m1.47bn2.70k--2.01--1.78-1.30-1.309.218.040.73859.916.84305,037.00-10.40---12.43--69.15---14.08--1.73-105.000.0506--11.03---135.09------
Evolent Health Inc2.46bn-104.23m1.68bn4.70k--1.60115.250.6814-0.9129-0.912921.5510.660.953--6.14524,309.40-2.79-9.60-3.58-12.5915.9624.50-2.93-13.66---0.55950.3285--45.2625.65-660.71---6.18--
AtriCure Inc447.57m-38.92m1.79bn1.20k--3.84--3.99-0.8322-0.83229.569.540.73651.638.41372,977.50-6.40-3.72-7.35-4.1074.7974.36-8.70-7.642.59-13.760.1194--20.8414.6434.49--46.56--
Rxsight Inc128.29m-30.69m1.80bn374.00--6.60--14.06-0.8194-0.81943.406.890.52121.996.32343,029.40-12.47---13.62--68.44---23.92--11.71--0.0005--81.77--27.19------
Patterson Companies, Inc.6.53bn168.41m1.83bn7.60k11.341.927.100.28011.831.8371.2210.802.275.8615.35859,640.705.841.1310.151.8121.0320.982.570.51570.67237.910.4474304.751.503.34-10.4218.102.170.00
Data as of Nov 12 2024. Currency figures normalised to STAAR Surgical Co's reporting currency: US Dollar USD

Institutional shareholders

62.94%Per cent of shares held by top holders
HolderShares% Held
Broadwood Capital, Inc.as of 30 Jun 202410.77m21.89%
BlackRock Fund Advisorsas of 30 Jun 20246.91m14.04%
The Vanguard Group, Inc.as of 30 Jun 20245.36m10.89%
SSgA Funds Management, Inc.as of 30 Jun 20241.93m3.92%
Baillie Gifford & Co.as of 30 Sep 20241.46m2.97%
Palo Alto Investors LPas of 30 Jun 20241.38m2.81%
Geode Capital Management LLCas of 30 Jun 20241.14m2.32%
Geneva Capital Management LLCas of 30 Sep 2024695.42k1.41%
Defender Capital LLCas of 30 Sep 2024677.62k1.38%
Dimensional Fund Advisors LPas of 30 Sep 2024636.44k1.29%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.